MSI-H And dMMR Global Market Report 2026

MSI-H (microsatellite instability-high) and dMMR (deficient mismatch repair) are genetic abnormalities in which the DNA repair system fails to correct replication errors, resulting in high mutation rates. These markers are commonly observed in certain cancers, including colorectal and endometrial cancers. Tumors with MSI-H and dMMR often respond well to immunotherapy due to their increased immunogenicity.

The primary treatment types for MSI-H and dMMR include immune checkpoint inhibitors (ICIs) and combination therapies. Immune checkpoint inhibitors are drugs that enhance the immune system's ability to attack cancer by blocking proteins such as PD-1, PD-L1, or CTLA-4, which tumors exploit to suppress immune responses. These therapies are used for various cancers, including endometrial, gastric, colorectal, small intestine, cervical cancers, and others, and are applicable across different stages, from early to advanced. Treatments are administered in hospitals, oncology clinics, research institutions, and homecare settings.

Tariffs have affected the MSI-H and dMMR market by increasing costs of imported diagnostic kits, sequencing reagents, and immunotherapy drugs. These impacts are most evident in advanced-stage cancer treatment and molecular diagnostics segments, particularly across North America, Europe, and Asia-Pacific regions. Higher tariffs have raised treatment and testing costs for hospitals and oncology clinics. However, tariffs have also encouraged local manufacturing of diagnostic assays and strengthened regional precision oncology capabilities.

The msi-h and dmmr market research report is one of a series of new reports from The Business Research Company that provides msi-h and dmmr market statistics, including msi-h and dmmr industry global market size, regional shares, competitors with a msi-h and dmmr market share, detailed msi-h and dmmr market segments, market trends and opportunities, and any further data you may need to thrive in the msi-h and dmmr industry. This msi-h and dmmr market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The msi-h and dmmr market size has grown exponentially in recent years. It will grow from $7.57 billion in 2025 to $9.32 billion in 2026 at a compound annual growth rate (CAGR) of 23.1%. The growth in the historic period can be attributed to discovery of msi-h and dmmr biomarkers, early success of immune checkpoint inhibitors, rising colorectal and endometrial cancer incidence, expansion of molecular diagnostics, regulatory approvals for biomarker-based therapies.

The msi-h and dmmr market size is expected to see exponential growth in the next few years. It will grow to $21.13 billion in 2030 at a compound annual growth rate (CAGR) of 22.7%. The growth in the forecast period can be attributed to growth in precision oncology adoption, increasing use of genomic testing in cancer care, expansion of immunotherapy indications, rising investment in biomarker research, growing clinical evidence supporting tumor-agnostic approaches. Major trends in the forecast period include increasing adoption of immunotherapy for msi-h and dmmr tumors, growing use of companion diagnostics for patient stratification, rising focus on tumor-agnostic cancer treatments, expansion of combination immunotherapy regimens, increasing awareness of biomarker-driven oncology.

The increasing prevalence of cancer is expected to drive the growth of the MSI-H and dMMR market in the coming years. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer cases is largely driven by aging populations, as the risk of developing cancer increases with age due to the cumulative effect of genetic mutations and prolonged exposure to risk factors. MSI-H and dMMR biomarkers are used to identify tumors with high mutation rates caused by defects in DNA repair mechanisms. These biomarkers guide immunotherapy decisions, as such tumors are more likely to respond to immune checkpoint inhibitors, and they also provide insights into prognosis and potential hereditary syndromes. For example, in January 2024, the American Cancer Society, a US-based non-profit organization, reported that in 2023, approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths occurred in the United States. These figures are projected to increase in 2024, with around 2,001,140 new cases and 611,720 deaths anticipated, underscoring the continued rise in cancer incidence and mortality. Consequently, the growing prevalence of cancer is fueling the expansion of the MSI-H and dMMR market.

Major companies in the MSI-H and dMMR market are focusing on innovative treatments, such as combination therapy, to improve efficacy and patient outcomes. Combination therapy for MSI-H and dMMR cancers involves using two or more treatment modalities, often combining immunotherapy agents like checkpoint inhibitors with chemotherapy, targeted therapy, or radiation. This approach aims to enhance treatment response, overcome resistance, and improve survival in patients with tumors exhibiting high microsatellite instability or deficient mismatch repair. For example, in April 2025, Bristol-Myers Squibb, a US-based pharmaceutical company, received FDA approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) with MSI-H or dMMR features. This approval represents a major advancement in treating this cancer subtype, offering a new therapeutic option that targets multiple pathways to improve patient survival and response rates while addressing unmet medical needs.

In December 2023, Owkin Inc., a France-based company specializing in AI-driven drug discovery and precision medicine, partnered with Merck & Co., Inc. to develop AI-powered digital pathology diagnostics for cancer. The collaboration aims to increase MSI-H testing rates across multiple cancer types in the EU, including endometrial, gastric, small intestinal, and biliary cancers, by using artificial intelligence to enhance diagnostic accuracy, streamline laboratory workflows, and better match patients with appropriate treatments. Merck & Co., Inc., a US-based pharmaceutical company, provides KEYTRUDA (pembrolizumab) for adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) cancers.

Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the msi-h and dmmr market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The MSI-H and dMMR market consists of revenues earned by entities by providing services such as genetic and molecular diagnostic testing, personalized treatment planning, and immunotherapy administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The MSI-H and dMMR market consists of sales of bispecific antibodies, monoclonal antibodies, and oncolytic virus therapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

MSI-H And dMMR Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses msi-h and dmmr market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for msi-h and dmmr ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The msi-h and dmmr market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs); Combination Therapy
• 2) By Indication: Endometrial; Gastric; Colorectal Cancer; Small Intestine Cancer; Cervical Cancer; Other Indications
• 3) By Stage: Early Stages; Advanced Stages
• 4) By End User: Hospitals; Oncology Clinics; Research Institutions; Homecare
• Subsegments:
• 1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors; Programmed Cell Death Ligand 1 Inhibitors; Cytotoxic T-Lymphocyte Antigen 4 Inhibitors
• 2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy; Immune Checkpoint Inhibitor + Targeted Therapy; Immune Checkpoint Inhibitor + Radiation Therapy; Immune Checkpoint Inhibitor + Other Immunotherapies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis International AG; AstraZeneca PLC; Bristol-Myers Squibb Company; GSK plc.; Takeda Pharmaceutical Company; Incyte Corporation; Exact Sciences Corp.; BeiGene LTD.; Summit Therapeutics Inc.; Tempus Labs Inc.; Guardant Health; NeoGenomics Laboratories Inc.; Promega Corporation; Caris Life Sciences; and Owkin.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.